Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/5/1538 |
| _version_ | 1797598617521881088 |
|---|---|
| author | Evi B. Struble Jonathan M. O. Rawson Tzanko Stantchev Dorothy Scott Marjorie A. Shapiro |
| author_facet | Evi B. Struble Jonathan M. O. Rawson Tzanko Stantchev Dorothy Scott Marjorie A. Shapiro |
| author_sort | Evi B. Struble |
| collection | DOAJ |
| description | Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well-suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research. |
| first_indexed | 2024-03-11T03:24:39Z |
| format | Article |
| id | doaj.art-ac65fe98a31d4dfb937e9e7ec43bf689 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T03:24:39Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-ac65fe98a31d4dfb937e9e7ec43bf6892023-11-18T02:53:01ZengMDPI AGPharmaceutics1999-49232023-05-01155153810.3390/pharmaceutics15051538Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody TherapiesEvi B. Struble0Jonathan M. O. Rawson1Tzanko Stantchev2Dorothy Scott3Marjorie A. Shapiro4Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD 20993, USADivision of Antivirals, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD 20993, USADivision of Biotechnology Review and Research 1, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD 20993, USADivision of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD 20993, USADivision of Biotechnology Review and Research 1, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD 20993, USAViral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well-suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research.https://www.mdpi.com/1999-4923/15/5/1538antiviral therapyantiviral antibodiesantibody combination therapyantibody potencypotency assays |
| spellingShingle | Evi B. Struble Jonathan M. O. Rawson Tzanko Stantchev Dorothy Scott Marjorie A. Shapiro Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies Pharmaceutics antiviral therapy antiviral antibodies antibody combination therapy antibody potency potency assays |
| title | Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
| title_full | Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
| title_fullStr | Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
| title_full_unstemmed | Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
| title_short | Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies |
| title_sort | uses and challenges of antiviral polyclonal and monoclonal antibody therapies |
| topic | antiviral therapy antiviral antibodies antibody combination therapy antibody potency potency assays |
| url | https://www.mdpi.com/1999-4923/15/5/1538 |
| work_keys_str_mv | AT evibstruble usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies AT jonathanmorawson usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies AT tzankostantchev usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies AT dorothyscott usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies AT marjorieashapiro usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies |